Expert opinion
Listen to experts in the field of atopic dermatitis (AD) offer insight into the latest in AD research including guideline recommendations, aetiology, pathophysiology and novel treatment options. Stay up-to-date by engaging with this podcast series to better inform your treatment decisions and improve the clinical outcomes of your patients.
Expert podcast series
Listen to this expert podcast series to update your knowledge of the latest treatments for atopic dermatitis. Learn more about:
- How the treatment landscape for atopic dermatitis is evolving with new treatments such as JAK inhibitors
- The indications and evidence for JAK inhibitor efficacy and safety
- Practical strategies to overcome challenges when integrating new atopic dermatitis treatments into clinical practice
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
Moderate-to-severe atopic dermatitis pathophysiology
Watch Professor Seemal Desai (biography) draw on his experience to provide up-to-date knowledge as he talks about the pathophysiology of moderate-to-severe atopic dermatitis and associated treatment options.
What is the importance of epidermal hyperplasia in atopic dermatitis?
A combination of factors influences the development of epidermal hyperplasia in atopic dermatitis. Hear Professor Desai add insight into what is known of its pathogenesis. Further your understanding of the pathways involved in epidermal hyperplasia, knowledge which is key to providing targeted therapeutics and realising improvements for patients.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
Pruritis in atopic dermatitis
Professor Martin Steinhoff’s (biography) interest in atopic dermatitis is mainly around the pathophysiology and management of pruritis and understanding the neuroimmunology of the condition. Watch the videos below to hear him share expertise in these areas.
What is the burden of atopic dermatitis for patients?
Without getting into the skin of a patient with atopic dermatitis, can you truly understand the severity of pruritis? Professor Steinhoff emphasises the many ways in which the burden of itching can impact an individual’s life – from serious limitations on everyday activities to life-changing psychological impact. You may identify with what you’ve have encountered in your own clinical practice as you hear about patients describing pruritis as the symptom for which they require most urgent help.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
Emerging treatments in moderate-to-severe atopic dermatitis
Watch Professor Thomas Bieber (biography) talk about emerging treatments for moderate-to-severe atopic dermatitis.
What notable emerging topical and systemic agents are currently in the pipeline?
Will the battle between biologics and small molecules benefit patients? Expand your knowledge on the pipeline of biologics and JAK inhibitors that are currently in development for moderate-to-severe atopic dermatitis, including tralokinumab, lebrikizumab, upadacitinib, and abrocitinib.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
Unmet needs and treatment goals in atopic dermatitis
In this expert interview with Professor Michael Cork (biography) discover the impact of atopic dermatitis and the unmet needs that remain in treating this disease with topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI).
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
PDE4 inhibition in atopic dermatitis
Explore how the phosphodiesterase-4 (PDE4) enzyme fits into the pathophysiology of atopic dermatitis with our expert Michael Cork, Professor of Dermatology at the University of Sheffield. Also learn about its potential as a therapeutic target and glimpse into the future with a look into upcoming clinical trials comparing PDE4 inhibitors to topical corticosteroids (TCS).
How is PDE4 involved in the pathophysiology of atopic dermatitis?
Professor Cork describes the central role of the PDE4 enzyme in regulating the release of a variety of inflammatory cytokines involved in the development of atopic dermatitis.
The pathophysiology of atopic dermatitis is complex and multifaceted, involving various elements such as skin barrier dysfunction, alterations to immune responses and environmental factors (Figure 1). Learn how elevated levels of PDE4 play a key role in the development of atopic dermatitis.
Figure 1: cAMP is present at high levels within a variety of cells with PDE4 regulating its breakdown. However, it has been shown that patients with atopic dermatitis display elevated levels of PDE4 in circulating inflammatory cells, resulting in a reduction in cAMP and an increase in the production of a variety of proinflammatory cytokines such as IL-4, IL-5 and IL-17. Adapted from: Purushothaman et al. 20185. AC, Adenylyl cyclase; ATP, adenosine triphosphate; AMP, adenosine monophosphate; cAMP, cyclic adenosine monophosphate; IgE, immunoglobulin E; IL, interleukin; PDE4, phosphodiesterase-4.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
References
- Paller AS, Mcalister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41(5):323–332.
- Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808–814.
- Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27(5):499–506.
- Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018;32(5):657–682.
- Purushothaman B, Arumugam P, Kulsi G, Song JM. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis. Eur J Med Chem. 2018;145:673–690.
- Oswald K. Atopic dermatitis: dupilumab and crisaborole could herald a new era in treatment. Pharm J. 2017;298(7898). doi:10.1211/pj.2017.20202337.
- Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e6.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
of interest
are looking at
saved
next event
This content has been developed by Medthority who previously received funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.